相关实验视频

Updated: May 9, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

鼻内融合抑制性脂可以防止子的SARS-CoV-2直接接触传播

Rory D de Vries¹, Katharina S Schmitz¹, Francesca T Bovier^2,3,4

¹Department of Viroscience, Erasmus MC, Rotterdam, Netherlands.

Science (New York, N.Y.)

|February 18, 2021

概括

新的脂融合抑制剂有效阻止了SARS-CoV-2感染. 每日鼻腔治疗完全防止了传染,为抗击COVID-19提供了潜在的预防策略.

科学领域:

病毒学
药物发现
传染性疾病

背景情况:

控制COVID-19大流行需要减少SARS-CoV-2的传播.
病毒进入宿主细胞是通过促进膜融合的尖端蛋白进行的.

研究的目的:

设计和评估新的脂融合抑制剂.
在动物模型中评估这些抑制剂对SARS-CoV-2传播的预防效果.

主要方法:

脂融合抑制剂旨在阻止尖端蛋白介导的膜融合.
进行了体外疗效和体内生物分布研究.
在SARS-CoV-2传播的模型中评估了一种二次性脂.

主要成果:

脂抑制剂在阻止病毒进入方面表现出有效性.
每天鼻入服用二次性脂完全防止了中SARS-CoV-2的传播.
在严格的共同养模式中,未经治疗的对照动物都被感染了.

结论:

脂融合抑制剂是预防SARS-CoV-2感染的有希望的策略.
鼻腔内脂可能提供一种稳定有效的预防措施来预防COVID-19的传播.
进一步的发展可能会导致易于翻译的鼻内预防.

更多相关视频

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation

A Fluorogenic Peptide Cleavage Assay to Screen for Proteolytic Activity: Applications for coronavirus spike protein activation

Published on: January 9, 2019

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

Published on: March 1, 2019

相关概念视频

Influenza

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...